Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 361

1.

Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.

Collarini EJ, Lee FE, Foord O, Park M, Sperinde G, Wu H, Harriman WD, Carroll SF, Ellsworth SL, Anderson LJ, Tripp RA, Walsh EE, Keyt BA, Kauvar LM.

J Immunol. 2009 Nov 15;183(10):6338-45. doi: 10.4049/jimmunol.0901373. Epub 2009 Oct 19.

3.
4.
5.

Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.

Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S.

Virology. 2008 Aug 15;378(1):79-85. doi: 10.1016/j.virol.2008.04.016. Epub 2008 Jun 16.

6.

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF.

J Infect Dis. 1997 Nov;176(5):1215-24.

PMID:
9359721
7.

Two neutralizing human anti-RSV antibodies: cloning, expression, and characterization.

Heard C, Brams P, Walsh E, Huynh T, Chamat S, Reff M, Owyang A, Shestowsky W, Newman R.

Mol Med. 1999 Jan;5(1):35-45.

8.

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.

J Mol Biol. 2007 May 4;368(3):652-65. Epub 2007 Feb 20.

PMID:
17362988
10.

Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.

Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF 3rd, Burton DR.

Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1386-90.

11.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22. Epub 2007 Oct 10.

12.

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM.

J Infect Dis. 2004 Sep 1;190(5):975-8. Epub 2004 Jul 27.

PMID:
15295704
14.

[Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].

Zeng RH, Gong W, Fang XP, Zhang ZY, Mei XG.

Sheng Wu Gong Cheng Xue Bao. 2005 Jul;21(4):534-9. Chinese.

PMID:
16176088
15.
16.

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.

Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA.

J Virol. 2004 Oct;78(20):11198-207.

17.

Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo.

Crowe JE Jr, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ, Pilkington GR.

J Infect Dis. 1998 Apr;177(4):1073-6.

PMID:
9534985
19.

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.

Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF.

J Mol Biol. 2005 Jul 1;350(1):126-44.

PMID:
15907931
20.

Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.

Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, Dillon SB.

Pediatr Res. 1995 Oct;38(4):543-50.

PMID:
8559607

Supplemental Content

Support Center